Skip to main content
Journals

Retrospective Study on Palpable Indurations After Cosmetic Filler Injection: Ultrasonic Characterization and Image-Guided Therapy

Aesthetic Surgery Journal
Aesthetic Surgery Journal

Authors: Xing Wang, MD , Fu-Jin Liu, MD , Chun-Lin Chen, MD, PhD , Jia-Ying Xu, MD , Zhong-Sheng Sun, MD , Chen Dong, MD ,Guo-Hao Yuan, MD , Li Ma, MD , Hai-Bin Wang, MD, PhD
Abstract: Minimally invasive filler injections are prevalent in aesthetic medicine. However, in recent years, the occurrence of complications has gradually increased. Current management lacks standardization, necessitating reliable imaging for diagnosis and treatment guidance. This study aimed to evaluate the diagnostic value of high-frequency ultrasound in filler-induced indurations and explore its significance in guiding treatment strategy selection. A retrospective analysis included 231 patients with indurations after filler injection (January 2023 to June 2025). All underwent high-frequency ultrasound (12-18 MHz); 70 received pathological biopsy. Biopsy was used to determine the nature of the lesions and establish the correlation between lesion type and sonographic features. Based on ultrasound characteristics, lesions were classified into 7 types and analyze the accuracy of ultrasound diagnosis and the efficacy of different treatment methods. The ultrasound–pathology concordance rate was 85.7%. The most common complications were accumulation of non-HA fillers (37.2%) and granuloma with non-HA fillers (22.5%). Non-HA filler granuloma responded better to noninvasive treatment (P < .001), while granuloma without residual filler and HA with granuloma favored invasive treatment (P = .001). Invasive treatment showed greater improvement in indurations (P < .001). High-frequency ultrasound accurately identifies types of complication, providing crucial evidence for individualized treatment selection.

JOURNAL ARTICLE

Related Articles

Melasma is a chronic, relapsing hyperpigmentation disorder that is difficult to treat, particularly in Fitzpatrick skin types III-V, where energy-based devices frequently induce postinflammatory hyperpigmentation (PIH). Radiofrequency microneedling (RFMN) has emerged as a promising alternative because it targets dermal pathology while minimizing epidermal injury.
Hyaluronidase is often described as “dissolving” dermal filler, but this term oversimplifies how the enzyme actually interacts with long-standing filler within living tissue. This article explains why hyaluronidase more accurately modifies a complex filler–tissue system rather than completely eliminating filler, and why clearer terminology improves patient understanding, clinical decision-making, and ethical practice in aesthetic medicine.
Conventional botulinum toxin type A (BoNT/A) products include non-therapeutic accessory proteins vary in composition and manufacturing processes, which may contribute to differences in purity and biochemical characteristics. YY001 (Retoxin®) is a novel recombinant BoNT/A manufactured via E. coli expression to reduce impurities, improve purity, and minimize immunogenic risk.